key: cord-0900615-2n6pakm9 authors: Mehta, Sapna A.; Leonard, Jeanette; Labella, Pauline; Cartiera, Katarzyna; Soomro, Irfana; Neumann, Henry; Montgomery, Robert A.; Ali, Nicole M. title: Outpatient management of kidney transplant recipients with suspected COVID‐19—Single‐center experience during the New York City surge date: 2020-07-06 journal: Transpl Infect Dis DOI: 10.1111/tid.13383 sha: edc4e2844e91c2c44937331bbd1a3c6f3b2ac45a doc_id: 900615 cord_uid: 2n6pakm9 Data describing the clinical progression of coronavirus disease 2019 (COVID‐19) in transplant recipients are limited. In New York City during the surge in COVID‐19 cases, a systematic approach to monitoring and triaging immunocompromised transplant patients was required in the context of strained healthcare resources, limited outpatient testing, and heightened hospital exposure risks. Public health guidance at the onset of the COVID‐19 outbreak recommended outpatient monitoring of mildly symptomatic patients without specific recommendations for special populations such as transplant recipients. We developed and implemented a systematic monitoring algorithm for kidney transplant recipients at our transplant center who reported mild symptoms suggestive of COVID‐19. We describe the outcomes of the first 44 patients monitored through this algorithm. A total of 44 kidney transplant recipients thought to be symptomatic for COVID‐19 disease were followed for a minimum of 14 days. The majority of mildly symptomatic patients (34/44) had clinical progression of disease and were referred to the emergency department where they all tested PCR positive and required hospitalization. More than half of these patients presented with hypoxia requiring supplemental oxygen, 39% were intubated within 48 hours, and 53% developed acute kidney injury but did not require dialysis. There were 6 deaths. During surge outbreaks, kidney transplant patients with even mild symptoms have a high likelihood of COVID‐19 disease and most will worsen requiring hospitalization for supportive measures. Earlier outpatient testing and hospitalization may improve COVID‐19 outcomes among transplant recipients. A standardized intake assessment and documentation template were created and implemented for incoming calls from patients with symptoms or potential COVID-19 exposures. Due to atypical presentations of other respiratory viral infections in immunosuppressed patients, our approach included a detailed assessment of patient-reported symptoms followed by daily telephone monitoring for changes or progression of symptoms over 14 days. We utilized our existing 24-hour on-call center staffed by a registered nurse or nurse practitioner (RN/NP) for patient calls and a templated electronic medical record (EMR) note to ensure comprehensive and consistent capture of clinical data and follow-up plans ( Figure 1 ). Best practices for staff and patient communication were followed including use of language interpreter services when indicated. Patients' self-reporting symptoms suspicious for COVID-19 were assessed for the need for immediate triage to the ED by discussion of the intake symptoms and epidemiologic information with a transplant nephrologist. Symptoms were assessed to be mild if there was cough, fever, fatigue, myalgias, headache, sore throat or gastrointestinal symptoms in the absence of shortness of breath, chest pain, or home pulse oximeter reading <92 percent. Patients with mild symptoms deemed safe to be monitored as outpatients were called daily for 14 days to assess for progression of symptoms and to guide further triage. The decreased number of non-urgent outpatient visits to our center allowed for the re-deployment of providers to the COVID-19 outpatient management center. Patients with progressive symptoms were referred to the ED. Progressive symptoms were defined but not limited to fever for >2 days, shortness of breath, chest pain, decreased oral intake, and worsening diarrhea. Four weeks after implementation of this outpatient strategy, we reviewed all patients to assess the number of cases requiring inpatient management and the number of cases confirmed with COVID-19 by diagnostic testing. School of Medicine Institutional Review Board. The data reported here were extracted from retrospective review of patient electronic medical records. From 3/15/2020 to 04/12/2020, a total of 44 kidney transplant recipients contacted the clinic reporting mild symptoms possibly F I G U R E 2 Patients managed through outpatient monitoring program related to COVID-19 and entered our outpatient monitoring system ( Figure 2 ). All 44 patients in this cohort have completed 14 days of monitoring or remain hospitalized. One of 44 patients (2.3%) tested positive for SARS-CoV-2 PCR at an outpatient community facility and never required hospitalization. Nine of 44 patients (20.4%) did not require hospitalization because symptoms resolved. Eight of these 9 patients were never tested for SARS-CoV-2 as access to outpatient testing was not available for clinically stable patients early in the outbreak. One of the 9 patients whose symptoms resolved was subsequently admitted for acute renal failure and during that admission was found negative for SARS-CoV-2 on PCR testing. Thirty-four of 44 (77.3%) patients had progression of symptoms requiring evaluation in the ED. All 34 patients tested positive for COVID-19 by nasopharyngeal swab SARS-CoV-2 PCR on presentation. Nine of 34 patients were discharged from the ED/short stay unit and 7 of these 9 were readmitted to the hospital with progressive illness within a median of 5 days (IQR 4-7.5) (Figure 3 ). Five of these 7 patients who returned to the hospital were severely hypoxic on readmission requiring supplemental high flow oxygen or intubation. Three of these 5 patients required intubation with 1 clinically recovered and 2 deceased. Baseline patient characteristics of the 34 patients hospitalized with progressive COVID-19 symptoms are shown in Table 1 The majority (56%) of patients had cough or fever as an initial symptom of COVID-19, while approximately 15% of patients reported diarrhea. Thirty-two of the 34 (94.1%) patients were lymphopenic on presentation with a median absolute lymphocyte count of 400 cells/ The maintenance immunosuppression regimen for nearly all patients For the 34 patients with progression from mild symptoms to hospitalization for COVID-19, the median time to ED referral for further evaluation was 5 days (IQR 1-7) after contacting our program, the median duration of symptoms prior to hospitalization was 8 days (QR 4.5-10), and the median length of hospitalization was 9.5 days (IQR F I G U R E 3 Readmissions for patients with COVID-19 after short stay/ED visit 5.25-15.75). One patient remains hospitalized in guarded condition. To date, there have been 6 deaths among the 35 patients with con- based on the progression of symptoms in our patient cohort we deem a symptom-based outpatient monitoring approach to be inadequate for our high-risk population. Our practice was modified to include SARS-CoV-2 PCR testing for symptomatic transplant recipients at our institution as a result of early findings from this algorithm. Prompt outpatient testing can allow earlier access to COVID-19 directed therapies and supportive care which are likely to improve associated patient outcomes. Allocation of testing resources should prioritize higher risk populations such as immunocompromised transplant recipients. We would like to acknowledge our kidney and liver transplant coordinators and nurse practitioners for their contributions to the implementation of our outpatient monitoring algorithm. All authors contributed to the conception and implementation of the out- Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) 2020 Update on COVID-19 for New York State Healthcare Providers Early outcomes of outpatient management of kidney transplant recipients with coronavirus disease 2019 Covid-19 and Kidney Transplantation COVID-19 in solid organ transplant recipients: Initial report from the US epicenter